Biosynex S.A.
ALBIO.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.01 | -0.09 | 0.02 |
| FCF Yield | -80.86% | -54.99% | -21.50% | 40.49% |
| EV / EBITDA | -4.28 | -13.25 | 1.75 | 0.87 |
| Quality | ||||
| ROIC | -13.03% | -16.91% | 11.04% | 49.96% |
| Gross Margin | -19.76% | 52.84% | 32.82% | 47.72% |
| Cash Conversion Ratio | 0.23 | 0.26 | 0.32 | 1.06 |
| Growth | ||||
| Revenue 3-Year CAGR | -19.86% | -37.59% | 8.50% | 123.57% |
| Free Cash Flow Growth | 69.59% | -95.74% | -127.68% | 303.29% |
| Safety | ||||
| Net Debt / EBITDA | -3.24 | -4.46 | -0.75 | -0.66 |
| Interest Coverage | -3.40 | -14.18 | 77.57 | 384.86 |
| Efficiency | ||||
| Inventory Turnover | 1.34 | 1.15 | 3.51 | 6.42 |
| Cash Conversion Cycle | 169.70 | 234.42 | 89.99 | 46.78 |